Novel Inflammatory Markers in Different Phenotypes of Severe Asthma

University of Pisa

Status: Unknown

Conditions: Asthma; Nasal Polyps

Treatments: Other: observational

Study type: Observational

Funder types: Other

Identifiers

NCT04888910

NIMISA

Details and patient eligibility

About

Asthma is a highly prevalent chronic airway inflammatory disease characterized by airway hyper-responsiveness, reversible airflow obstruction and increased mucus secretion, involving large and small airways. An emerging sub-phenotype of severe asthma is the late onset disease associated with nasal polyposis, a frequent co-morbidity that significantly impacts lung function and symptom control. On the basis of the infiltrate found in the sputum, asthma can be divided into four distinct phenotypes: eosinophilic, neutrophilic, mixed granulocytic and pauci-granulocytic. The majority of patients with eosinophilic asthma are sensitive to corticosteroids, and biological therapies targeting eosinophils (anti-Interleukin (IL)-5 and anti-IL5R) have been recently approved. However, it is known that some asthmatics, particularly those who have severe disease and are resistant to corticosteroids, have elevated neutrophil counts in the airway where they play a vital role in the exacerbation of the disease. However, the precise role of neutrophils in severe asthma and the mechanisms involved in neutrophil-induced tissue damage have not been clarified yet.

The hypothesis of the study is that neutrophils and eosinophils can contribute to the severity of asthma by changing their phenotypes according to the airway environment. Thus, a better understanding of the roles of neutrophils and eosinophils in severe asthma may lead to the identification of novel biomarkers and the development of new therapeutic approaches in different phenotypes of severe asthma.

Enrollment: 80 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female
• age (18-65 years)
• Diagnosis of severe asthma according to the European Respiratory Society (ERS) and American Thoracic Society (ATS) definition, with and without nasal symptoms
• normal pulmonary function post-therapy (FEV1 post-bronchodilation: greater than 80% of the predicted value, with FEV1/ vital capacity (VC) > 88-89% - for males and females, respectively - of the predicted value)
• non reversible chronic airflow limitation (FEV1 post-bronchodilation: lower than 70% of the predicted value, with FEV1/VC < 88-89% of the predicted value)
• Signing of the informed consent

Exclusion criteria

• Referred Pregnancy
• Use of therapy with beta-blockers
• Smoking (current or within the previous 3 months)
• Negation to participate to the study
• Current upper and lower airways infectious diseases
• Current systemic infectious diseases

Trial design

80 participants in 2 patient groups

asthma with nasal polyps

Description:

severe asthma with involvement of the upper airways (chronic rhinosinusitis with nasal polyps)

Treatment:

Other: observational

severe asthma without nasal polyps

Description:

severe asthma without involvement of the upper airways

Treatment:

Other: observational